# Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

> **NCT01298713** · PHASE2 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 111 (actual)

## Conditions studied

- Breast Neoplasms
- mTor Protein

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01298713
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-06
- **Final completion:** 2018-09-12
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2023-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01298713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01298713, "Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01298713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*